Table III.
Prognostic factors for disease-free survival in 167 patients with breast cancer.
| Variables | n | Univariate Hazard ratio | 95% CI | P | Multivariate Hazard ratio | 95% CI | P |
|---|---|---|---|---|---|---|---|
| Age (>60) | 59 | 1.06 | 0.49–2.17 | 0.879 | |||
| UICC T factor (T2-4) | 90 | 3.96 | 1.73–10.7 | <0.001a | 1.85 | 0.67–5.65 | 0.239 |
| Lymph node metastasis (positive) | 82 | 4.98 | 2.18–13.4 | <0.001a | 2.84 | 0.79–10.0 | 0.107 |
| UICC pathological stage (III/IV) | 36 | 7.73 | 3.78–16.4 | <0.001a | 4.80 | 1.80–14.9 | 0.001a |
| ER status (negative) | 40 | 2.02 | 0.93–4.14 | 0.073 | |||
| PgR status (negative) | 52 | 1.81 | 0.87–3.67 | 0.112 | |||
| HER2 status (positive) | 39 | 2.31 | 1.09–4.76 | 0.031a | 0.94 | 0.42–2.08 | 0.883 |
| Triple-negative (yes) | 18 | 2.37 | 0.88–5.40 | 0.084 | |||
| Adjuvant chemotherapy (yes) | 94 | 2.37 | 1.10–5.65 | 0.026a | 0.32 | 0.09–1.07 | 0.064 |
| The low RFX1 group | 124 | 5.69 | 1.72–35.2 | 0.002a | 4.77 | 1.32–30.9 | 0.014a |
a
Statistically significant in multivariate analysis (P<0.05). CI, confidence interval; UICC, Union for International Cancer Control; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor 2. Univariate analysis was performed using the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model.